絞り込み

16404

広告

神戸マラソンに約2万人 健脚競う (NHK)

阪神・淡路大震災で受けた支援への感謝と復興した町の様子を伝えようと始まった神戸マラソンが19日に行われ、およそ2万人が健脚を競いました。 神戸マラソンはことしで...

  1. 食物アレルギー 治療や検査で9人が重い症...
  2. 冬の登山に注意を 富士山登山道で呼びかけ...
  3. 歴史教科書、龍馬が消える? 高校の用語半...
  4. クルマ社会に革新をもたらす10の「注目ス...

ニュース一覧

Treatment of Helicobacter pylori infection 2017.

著者 O'Connor A , Lamarque D , Gisbert JP , O'Morain C
Helicobacter.2017 Sep ; 22 Suppl 1():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (55view , 0users)

Full Text Sources

This review summarizes important studies regarding Helicobacter pylori therapy published from April 2016 to April 2017. The main themes that emerge involve studies assessing the efficacy of bismuth and nonbismuth quadruple regimens. While in recent years, much of the emphasis on the use of bismuth has focussed on its utility in a second-line setting, an increasing number of studies this year have shown excellent efficacy in first-line therapy. The efficacy of bismuth as a second-line after sequential and concomitant therapy was particularly noteworthy. Antibiotic resistance was more intensely studied this year than for a long time, and definite trends are presented regarding an increase in resistance, including the fact that clarithromycin resistance in particular is now at a level where the continued use of clarithromycin triple therapy first-line as a mainstream treatment is not recommended. Another exciting trend to emerge this year is the utility of vonoprazan as an alternative to PPI therapy, especially in resistant and difficult-to-treat groups.
PMID: 28891137 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード